Lab Pays $4M to Settle Doctor-Kickback Claims
By Bianca Bruno,
Courthouse News Service
| 12. 30. 2015
Untitled DocumentA San Diego-based medical diagnostics laboratory paid over $4 million to settle claims it gave kickbacks to physicians who referred patients to the company for genetic testing.
Pathway Genomics Corporation paid $4,036,622.74 in a civil settlement of claims it paid doctors in exchange for patient referrals for their genetic testing kits that analyze the risks for certain genetic cancers and diseases and test the responsiveness of certain medications. The tests are performed using a saliva sample that is typically collected by a patient's doctor and mailed to Pathway's lab for testing.
Federal investigators found Pathway violated the False Claims Act by offering physicians and medical groups reimbursements of up to $20 for each saliva kit they submitted for genetic testing. Individual physicians cashed in as much as $13,534 in kickbacks from Pathway and most had not ordered the costly genetic tests prior to enrolling in the reimbursement program, according to U.S. Attorney Laura Duffy.
Prosecutors also claimed Pathway billed federal health care programs such as Medicare and TRICARE to foot the cost of the testing.
Pathway has since...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
